Navigation Links
Serendipity leads to lifesaving discovery
Date:5/11/2011

About two years ago, Dr. Philippe Gros, a McGill University professor in the Department of Biochemistry and a Principal Investigator in thd McGill Life Sciences Complex, described a mouse mutant that was immunodeficient and hypersensitive to the Bacille Calmette-Gurin (BCG) vaccine and to tuberculosis (TB). In this model, Gros's team had found that the immunodeficiency was caused by a mutation in a regulatory protein of the immune system named IRF8.

A year later, a physician in Newcastle who had heard about Gros's work, contacted him about a three-month-old patient who was gravely ill and dying. The infant was suffering from an infection following a perinatal BCG vaccination. She had been treated aggressively with antibiotics but relapsed with additional infections. In addition, she showed a complete absence of circulating monocytes and dendritic cells in her blood two critically important types of immune cells. She was admitted into an ICU and it seemed nothing could be done to save her.

The clinical aspects of the infant's immuno-deficiency were so strikingly similar to those of Gros's earlier mouse model findings, that his research team investigated the human IRF8 gene for the presence of mutations in this infant. Dr. Gros group also examined IRF8 in a number of additional clinical cases of disseminated BCG infection following vaccination.

What they found were two distinct disease-causing mutations one that causes the severe reaction seen in the infant (autosomal recessive) and requires stem cell transplantation, and the other that causes a milder form of disease (autosomal dominant).

These findings, recently published in the New England Journal of Medicine, point to a critical role for IRF8 in the development and function of monocytes and dendritic cells and in protecting against mycobacterial infections like TB in humans.

According to Gros, the best part of this story is that the infant received the much needed stem cell transplant that ultimately cured her. Based on the team's research, her doctors were going to transplant her with one of the parents' cells as they were found to be a perfect match. However, when the team learned that the father was carrying one copy of the dysfunctional gene, and knowing that such a situation is deleterious in mice, the physicians opted instead to graft her with an unrelated donor.

"I think this is a great example of the 'discovery pipeline' we have tried to set up at the Complex Traits Group lab," said Gros. "This began as basic research. It evolved from genetic discoveries in mouse models through to validation in humans and knowledge translation to a positive clinical outcome."

"This is archetypal translational research," said Dr. Richard I. Levin, Vice-Principal of Health Affairs and Dean of Medicine at McGill. "When results from lab work conducted in the Life Sciences Complex can be shared across the ocean in context and in time to save a child's life, we know our objectives are being fulfilled."


'/>"/>

Contact: Allison Flynn
allison.j.flynn@mcgill.ca
514-398-7698
McGill University
Source:Eurekalert

Related biology news :

1. ISU research leads to understanding of how crops deal with stress -- yields biggest enemy
2. Food safety study of beef trim leads to ongoing research collaboration
3. New leads on the causes of alcoholism
4. Jan-Åke Gustafsson leads team with $5.2M for prostate cancer research
5. MU researcher leads new $6.6 million study that could lead to better corn plants
6. UF Pine lsland pollen study leads to revision of states ancient geography
7. Relaxation leads to lower elasticity
8. Pollution with antibiotics leads to resistant bacteria
9. Pheromone increases foraging honey bees, leads to healthier hives
10. Massive Daphnia genome leads to understanding gene-environment interactions
11. Manchester leads green chemical training push
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, ... begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. ... healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed on ...
(Date:2/23/2017)... NC (PRWEB) , ... February 23, 2017 , ... ... to announce a new partnership with Compass Research . GGI's mission is to ... a vaccine to a child in need in honor of each clinical trial volunteer. ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members of ... Fellows of the Society this year, the Fellows Committee has announced. The honor ... optics, photonics, and imaging as well as their service to the Society and ...
Breaking Biology Technology: